700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Yavuz S Silay
Therapeutic Medical Head
Teva Neurosciences Commercial Organization
Dr. Silay is an Executive Physician Scientist, certified Clinical Research Professional in the Pharmaceutical industry with an Executive MBA degree from the Oline Business School at Washington University in St. Louis which is ranked #2 by Wall Street Journal. Dr. Silay is a member of American Academy of Neurology, DIA (Drug Information Association) SIAC’s for Good Clinical Practice/Quality Assurance Special Interest Activity Community (GCP/QA SIAC), Clinical Trial Registry/Results Disclosure Working Group (CTR/RD Working Group), Natural Health Products, MDS (Movement Disorder Society) current chair of TABID (Turkish American Business Improvement Council) for Healthcare and Pharmaceutical Industry, Charter and previous president of AMSA (American Medical Student Association) Turkey and previous president of SOCRA (Society of Clinical Research Associates) in New Jersey. Dr. Silay, a permanent resident of U.S.A. was born in Turkey and educated in Turkey, Germany and U.S.A. He completed his medical school from The University of Ankara in Turkey and his internship at Baylor College of Medicine and University of Texas in Houston, Texas. He was trained in a Physician Scientist Training Program at The MD Anderson Cancer Center of University of Texas. As a prolific scientific writer he published extensively with more than 15 peer reviewed article and more than 50 platform and abstract presentation at the academic and industry level in national and international meetings. Dr. Silay joined Teva Neuroscience on May 2009 and is currently the Head of Clinical and Medical Parkinson’s franchise as the Director of Scientific Affairs and Medical Research in U.S Headquarter in Kansas City reporting to Chief Medical Officer and VP of Medical Affairs. He is also responsible for the Parkinson’s disease Investigator Initiated Trials, Phase IIIB, Phase IV trials and for developing relationships with Key Opinion Leaders in the field of Neurology. He gained experience in therapeutic areas within pulmonary critical care, transplant, CNS and rheumatologic conditions such as, Fibromyalgia, Alzheimer, MS, Epilepsy, Autism and Parkinson’s disease.
Clinical development and medical affairs experience and interest in Internal Medicine (Pulmonary & Critical care, Asthma, CF, Sarcoidosis, Lung transplant Diabetic Neuropathy), Neurology (Movement disorders, Parkinson′s Huntington′s, Tourette, Alzheimer, DBS, Botox, Autism, Epilepsy, Head trauma), Psychiatry (Schizophrenia, Bipolar), Rheumatology, Pain (Fibromyalgia, Osteoarthritis), CFS, GI (anti emetics), Growth Hormone, Hematology, Oncology, Women′s health.